Coston McIsaac & Partners’s Anavex Life Sciences AVXL Stock Holding History

Coston McIsaac & Partners’s Portfolio AVXL Stock Details AVXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$0	Hold	200	–	–	﹤0.01%	844
2026 Q1	$0	Hold	200	–	–	﹤0.01%	835
2025 Q4	$0	Hold	200	–	–	﹤0.01%	828
2025 Q3	$1K	Hold	200	–	–	﹤0.01%	745
2025 Q2	$1K	Hold	200	–	–	﹤0.01%	719
2025 Q1	$1K	Hold	200	–	–	﹤0.01%	705
2024 Q4	$2K	Hold	200	–	–	﹤0.01%	669
2024 Q3	$1K	Hold	200	–	–	﹤0.01%	705
2024 Q2	$0	Hold	200	–	–	﹤0.01%	734
2024 Q1	$1K	Hold	200	–	–	﹤0.01%	675
2023 Q4	$1K	Hold	200	–	–	﹤0.01%	670
2023 Q3	$1K	Buy	+200	New	+$1.59K	﹤0.01%	672

Other funds holding AVXL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Coston McIsaac & Partners's AVXL Position: Q2 2026 in Review

Coston McIsaac & Partners held its Anavex Life Sciences (AVXL) position steady in Q2 2026 at 200 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #844.

Coston McIsaac & Partners first reported a position in AVXL in Q3 2023 and has held it in 12 quarters since. The position peaked at $2K in Q4 2024. 179 funds tracked by Wall St. Rank hold AVXL as of Q2 2026.

Coston McIsaac & Partners held 200 shares of Anavex Life Sciences worth $0 as of Q2 2026.
Coston McIsaac & Partners left its Anavex Life Sciences share count unchanged in Q2 2026.
Anavex Life Sciences made up ﹤0.01% of Coston McIsaac & Partners's portfolio in Q2 2026, its #844 holding.
Coston McIsaac & Partners first reported a position in Anavex Life Sciences in Q3 2023 and has held it in 12 quarters since.
Coston McIsaac & Partners's Anavex Life Sciences position peaked at $2K in Q4 2024.
179 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2026.

Based on Coston McIsaac & Partners's 13F filing for Q2 2026, filed 12 Aug 2026.